Earendil Labs announced a $787 million financing to accelerate an AI‑driven biologics R&D engine and advance a broad pipeline of antibodies, bispecifics and ADCs across autoimmune and oncology indications. Founder and CEO Jian Peng said the capital lets the company operate at a “fundamentally different scale,” moving multiple programs toward clinical testing while expanding R&D infrastructure in the U.S. and China. The round included strategic investors such as Sanofi and large VC funds; Earendil lists more than 40 programs and several collaborations already in place. The raise underscores continued investor appetite for AI‑enabled drug discovery at large scale.